17 November 2026 | Tuesday | News
Image Source: Public Domain
Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -
Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP). The U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate-to-severe LP.
LP is a chronic, CD8 cytotoxic T cell-driven inflammatory disease that can cause painful oral erosions, permanent scarring hair loss, and genital lesions, and is associated with a risk of malignancy in oral LP. Modzatinib is a potential first-in-class oral therapy with a unique mechanism that inhibits both ITK and JAK3, potentially addressing LP at multiple points in its immune pathology. ITK inhibition blocks T-cell receptor signaling upstream, reducing T cell activation, CD8 T cell-mediated cytotoxicity, and inflammatory cytokine production, while JAK3 inhibition blocks downstream cytokine signaling to limit T cell proliferation, activation, and survival.
“We are excited to initiate the ALPHA trial, particularly given the unmet medical need in lichen planus and the mechanistic potential for modzatinib in this indication,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Modzatinib has demonstrated activity in multiple non-clinical disease models, including severe alopecia areata, vitiligo, and rheumatoid arthritis, as well as in a Phase 2a trial in atopic dermatitis with rapid and sustained improvements across clinical and patient-reported measures of disease severity, pruritus, and quality of life. This provides support for its continued development across immuno-inflammatory diseases. There are no FDA-approved therapies for people living with this debilitating disease, and we believe that modzatinib has the potential to be the first mechanistically complete oral therapy in this setting.”
The ALPHA trial is a randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of modzatinib at two dose levels compared with placebo in approximately 100 participants with biopsy-proven, moderate-to-severe LP not adequately controlled with topical therapies. The trial is designed to include three patient cohorts: oral erosive lichen planus, cutaneous lichen planus (CLP), and lichen planopilaris (LPP). The primary endpoints are change from baseline in activity score of the Oral Disease Severity Score (ODSS) at Week 16 (OLP), modified Lichen Planus Area and Severity Index (LPASI) score at Week 16 (CLP), and Lichen Planopilaris Activity Index (LPPAI) score at Week 24 (LPP). A variety of secondary and exploratory endpoints will also be assessed.
Select Upcoming Milestones
Modzatinib: Top line results from the OLP cohort are expected in the second half of 2027.
ATI-9494 (ITK/TXK inhibitor): Aclaris expects to file the IND this quarter. The planned Phase 1 clinical program will evaluate single (SAD) and multiple ascending doses (MAD) of ATI-9494 followed by a proof-of-concept portion in an undisclosed indication. The Company expects to initiate the trial in the first quarter of 2027.
ATI-052 (anti-TSLP/IL-4Rα bispecific antibody): Following the recent positive primary analysis results from Phase 1b proof-of-concept trials (press release here), Aclaris expects to prioritize the development of this molecule in eosinophilic esophagitis (EoE). The Company intends to initiate the Phase 2b trial of ATI-052 in EoE in the first quarter of 2027.
© 2026 Biopharma Boardroom. All Rights Reserved.